Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 5, 2012, Pages 440-446

  Breeuwsma, A J ^a   Rybalov, M ^a   Leliveld, A M ^a   Pruim, J ^a   De Jong, I J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Choline; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY;

AGED; CARBON RADIOISOTOPES; CHOLINE; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME-TO-TREATMENT;

EID: 84871813530     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
2. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:869-75.
3. Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:941-7. (Pubitemid 27353672)
4. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005 08;236:545-53.
5. Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009;103:578-87.
6. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010;77:160-4.
7. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8.
8. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxy-glucose-positron emission tomography. J Urol 2003;169:1337-40. (Pubitemid 36323779)
9. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007;100:786-93. (Pubitemid 47360183)
10. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23. (Pubitemid 350234152)
11. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach Iii M et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.
12. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev 2011:CD007234.
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. (Pubitemid 29211767)
14. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155.
15. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58:382-90. (Pubitemid 38714445)
16. National Institute of Mental Health. Observation or Radical Treatment in Patients With Prostate Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [Internet]. Available at http:// clinicaltrials.gov/ct2/show/NCT00499174 [cited 2012, Jun 27].
17. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004;7:211-6. (Pubitemid 41741505)
18. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced us for detection. Radiology 2001;219:219-25. (Pubitemid 32234077)
19. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47:225-31. (Pubitemid 26075278)
20. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van PH et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51. (Pubitemid 41278578)
21. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23. (Pubitemid 350234152)
22. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006,8:43-8. (Pubitemid 44193401)
23. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008;113:895-904.
24. Picchio M, Landoni C, Messa C, Gianolli L, Matarrese M, De Cobelli F et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 2002;179:482-4. (Pubitemid 34785658)
25. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8.
26. Maffezzini M. High-risk prostate cancer is worth further risk stratification. Eur Urol 2008;53:872-3. (Pubitemid 351434500)
27. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668-73. (Pubitemid 40897489)
28. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5. (Pubitemid 39586006)
29. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al. Detection of lymph-node metastases with integrated [11C] choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007;52:423-9. (Pubitemid 46963456)